Literature DB >> 3311359

Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host.

S A Beck1, M J Tisdale.   

Abstract

Animals given transplants of the MAC16 colon adenocarcinoma show a progressive decrease in carcass weight as the tumor size increases without a reduction in either fluid or caloric intake when compared with non-tumor-bearing controls. There is a decrease in both carcass fat and muscle mass which is directly proportional to the weight of the tumor. In male animals weight loss occurs when the tumor mass comprises more than 0.3% of the body weight and reaches 30% when the tumor represents 3% of the body weight. There is evidence for the production by the tumor of both lipolytic and proteolytic factors, which may be responsible for the cachexia, since two related mouse adenocarcinomas, which do not produce weight loss, have little lipolytic or proteolytic activity. The lipolytic factor is nondialyzable and is destroyed by both heat and acid. Both insulin and 3-hydroxybutyrate suppress the lipolytic activity of the tumor extract. The MAC16 tumor also contains a serine protease, the activity of which is also completely abolished by insulin and 3-hydroxybutyrate. Animals bearing the MAC16 tumor have an elevated plasma lipolytic and proteolytic activity when compared with non-tumor-bearing controls, suggesting a peripheral effect of the tumor products. The catabolic factors elaborated by the MAC16 adenocarcinoma may be responsible for the loss of both the fat and nonfat carcass mass, but they do respond to normal metabolic controls.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3311359

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Anorexic contribution to increased linoleate mobilization and oxidation in lymphoma-bearing mice.

Authors:  R Kannan; M Gan-Elepano; N Baker
Journal:  Lipids       Date:  1992-02       Impact factor: 1.880

2.  Effect of cancer cachexia on triacylglycerol/fatty acid substrate cycling in white adipose tissue.

Authors:  S A Beck; M J Tisdale
Journal:  Lipids       Date:  2004-12       Impact factor: 1.880

Review 3.  Cancer cachexia.

Authors:  M J Tisdale; S A Beck
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

Review 4.  Muscle alterations in the development and progression of cancer-induced muscle atrophy: a review.

Authors:  Megan E Rosa-Caldwell; Dennis K Fix; Tyrone A Washington; Nicholas P Greene
Journal:  J Appl Physiol (1985)       Date:  2019-11-14

5.  C-reactive protein levels and vitamin d receptor polymorphisms as markers in predicting cachectic syndrome in cancer patients.

Authors:  Tiziana Punzi; Ariele Fabris; Gabriele Morucci; Paolo Biagioni; Massimo Gulisano; Marco Ruggiero; Stefania Pacini
Journal:  Mol Diagn Ther       Date:  2012-04-01       Impact factor: 4.074

6.  Effect of human mammary MX-1 tumor on plasma free fatty acids in fasted and fasted-refed nude mice.

Authors:  C Lin; W Blank; R L Ceriani; N Baker
Journal:  Lipids       Date:  1992-01       Impact factor: 1.880

7.  Turnover and fate of plasma free fatty acids in briefly-fasted lymphoma-bearing mice.

Authors:  N Baker; M Gan-Elepano; B A Guthrie; J F Mead
Journal:  Lipids       Date:  1989-12       Impact factor: 1.880

8.  A sarcoma-derived protein regulates hepatocyte metabolism via autocrine production of tumor necrosis factor-alpha.

Authors:  C P Fischer; B P Bode; W W Souba
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

9.  Metabolic substrate utilization by tumour and host tissues in cancer cachexia.

Authors:  H D Mulligan; M J Tisdale
Journal:  Biochem J       Date:  1991-07-15       Impact factor: 3.857

10.  Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model.

Authors:  H K van Halteren; G P A Bongaerts; C A M Verhagen; Y J L Kamm; J L Willems; G J Grutters; J P Koopman; D J Th Wagener
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-27       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.